[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:hairy-cell-leukemia-variant":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":28,"states":29},"Hairy Cell Leukemia Variant",3,[7,15,22],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04322383","Binimetinib for People With Relapsed\u002FRefractory BRAF Wild Type Hairy Cell Leukemia and Variant",[11],"Phase 2","RECRUITING","2026-08-26T02:17:33.807405Z","2026-07-24T01:27:14.929254Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT04815356","Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed\u002FRefractory Hairy Cell Leukemia and Variant",[19],"Phase 1","2026-08-26T02:15:53.461103Z","2026-05-05T02:43:27.133485Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT06311227","Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia",[11],"2026-08-26T02:15:27.567165Z","2026-05-05T02:35:31.905233Z",[],[30],{"state":31,"count":5,"slug":32},"Maryland","maryland"]